全文获取类型
收费全文 | 1836128篇 |
免费 | 131787篇 |
国内免费 | 4072篇 |
专业分类
耳鼻咽喉 | 24284篇 |
儿科学 | 60901篇 |
妇产科学 | 49856篇 |
基础医学 | 262024篇 |
口腔科学 | 52923篇 |
临床医学 | 162183篇 |
内科学 | 359221篇 |
皮肤病学 | 42610篇 |
神经病学 | 144444篇 |
特种医学 | 71387篇 |
外国民族医学 | 266篇 |
外科学 | 280193篇 |
综合类 | 39861篇 |
现状与发展 | 4篇 |
一般理论 | 562篇 |
预防医学 | 131076篇 |
眼科学 | 44045篇 |
药学 | 133702篇 |
7篇 | |
中国医学 | 4760篇 |
肿瘤学 | 107678篇 |
出版年
2021年 | 13819篇 |
2019年 | 14595篇 |
2018年 | 22299篇 |
2017年 | 17173篇 |
2016年 | 19314篇 |
2015年 | 22010篇 |
2014年 | 29373篇 |
2013年 | 42444篇 |
2012年 | 59701篇 |
2011年 | 61973篇 |
2010年 | 36645篇 |
2009年 | 33808篇 |
2008年 | 58048篇 |
2007年 | 62050篇 |
2006年 | 62553篇 |
2005年 | 60203篇 |
2004年 | 58006篇 |
2003年 | 55357篇 |
2002年 | 53455篇 |
2001年 | 96077篇 |
2000年 | 97954篇 |
1999年 | 80877篇 |
1998年 | 20997篇 |
1997年 | 18337篇 |
1996年 | 18158篇 |
1995年 | 17386篇 |
1994年 | 15912篇 |
1993年 | 14637篇 |
1992年 | 59270篇 |
1991年 | 57151篇 |
1990年 | 54852篇 |
1989年 | 52516篇 |
1988年 | 47692篇 |
1987年 | 46490篇 |
1986年 | 43696篇 |
1985年 | 41388篇 |
1984年 | 30478篇 |
1983年 | 25823篇 |
1982年 | 14523篇 |
1979年 | 26749篇 |
1978年 | 18481篇 |
1977年 | 15678篇 |
1976年 | 14531篇 |
1975年 | 15545篇 |
1974年 | 18645篇 |
1973年 | 17869篇 |
1972年 | 16593篇 |
1971年 | 15367篇 |
1970年 | 14228篇 |
1969年 | 13275篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
121.
122.
123.
Anders Elm Pedersen Esben Gjerløff Wedebye Schmidt Jesper Freddie Sørensen Carsten Faber Boye Schnack Nielsen Kim Holmstrøm Silje Haukali Omland Peter Tougaard Søren Skov Bo Bang 《APMIS : acta pathologica, microbiologica, et immunologica Scandinavica》2015,123(7):547-555
TL1A is a TNF‐like cytokine which has been shown to co‐stimulate TH1 and TH17 responses during chronic inflammation. The expression of this novel cytokine has been investigated in inflammatory disorders like rheumatoid arthritis and inflammatory bowel disease, but little is known about expression and induction in psoriasis. Indeed, the pathogenesis in psoriasis is still not fully understood and it is speculated that cytokines other than TNF‐α are important in subsets of patients. Also, for patients with severe disease that are treated with systemic anti‐TNF‐α blockade, novel candidates to be used as disease and response biomarkers are of high interest. Here, we demonstrate TL1A expression in biopsies from psoriatic lesions. Also, we investigated spontaneous and induced TL1A secretion from PBMCs and blood levels from a cohort of psoriasis patients. Here, increased spontaneous secretion from PBMCs was observed as compared to healthy controls and a small subset of patients had highly elevated TL1A in the blood. Interestingly, activation of PBMCs with various cytokines showed a decreased sensitivity for TL1A activation in psoriasis patients compared to healthy controls.TL1A levels in blood and biopsies could not be correlated with disease activity with this patient cohort. Thus, additional large‐scale studies are warranted to investigate TL1A as a biomarker. 相似文献
124.
Iclea Rocha Gama Euclides Marinho Trindade-Filho Suzana Lima Oliveira Nassib Bezerra Bueno Isabelle Tenório Melo Cyro Rego Cabral-Junior Elenita M. Barros Jaqueline A. Galvão Wanessa S. Pereira Raphaela C. Ferreira Bruna R. Domingos Terezinha da Rocha Ataide 《Metabolic brain disease》2015,30(1):93-98
125.
126.
127.
128.
129.
130.
William G. Breen Krishan R. Jethwa Nathan Y. Yu Grant M. Spears William S. Harmsen Robert C. Miller Jonathan B. Ashman William G. Rule Terence T. Sio Michelle A. Neben-Wittich Michael G. Haddock Amit Mahipal Mark J. Truty Christopher L. Hallemeier Kenneth W. Merrell 《Practical radiation oncology》2021,11(1):e63-e69
PurposeOur purpose was to determine the effect of chemoradiotherapy (CRT) on patient-reported quality of life (QOL) for patients with intact pancreas cancer.Methods and MaterialsWe reviewed a prospective QOL registry for patients with intact, clinically localized pancreatic ductal adenocarcinoma treated with CRT between June 2015 and November 2018. QOL was assessed pre-CRT (immediately before CRT, after neoadjuvant chemotherapy) and at the completion of CRT with the Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) and its component parts: FACT-General (FACT-G) and hepatobiliary cancer subscore (HCS). A minimally important difference from pre-CRT was defined as ≥ 6, 5, and 8 points for FACT-G, HCS, and FACT-Hep, respectively.ResultsOf 157 patients who underwent CRT, 100 completed both pre- and post-CRT surveys and were included in the primary analysis. Median age at diagnosis was 65 years (range, 23-90). National Comprehensive Cancer Network resectability status was resectable (3%), borderline resectable (40%), or locally advanced (57%). Folinic acid, 5-fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) (75%) or gemcitabine and nab-paclitaxel (42%) were given for a median of 6 cycles (range, 0-42) before CRT. Radiation therapy techniques included 3-dimensional conformal (22%), intensity modulated photon (55%), and intensity modulated proton (23%) radiation therapy to a median dose of 50 Gy (range, 36-62.5). Concurrent chemotherapy was most commonly capecitabine (82%). Sixty-three patients (63%) had surgery after CRT. The mean decline in FACT-G, HCS subscale, and FACT-Hep from pre- to post-CRT was 3.5 (standard deviation [SD], 13.7), 1.7 (SD 7.8), and 5.2 (SD 19.4), respectively. Each of these changes were statistically significant, but did not meet the minimally important difference threshold. Pancreatic head tumor location was associated with decline in FACT-Hep. Nausea was the toxicity with the greatest increase from pre- to post-CRT by both physician-assessment and patient-reported QOL.ConclusionsFor patients with intact pancreatic adenocarcinoma, modern CRT is well tolerated with minimal decline in QOL during treatment. 相似文献